Application of Omics-Based Strategies for Improved Diagnosis and Treatment of Endocrine Hypertension

Abstract

Arterial hypertension affects up to 45% of the general population and is responsible for 7.1 million deaths per year worldwide. We will define specific omics profiles for patients with a range of hypertension-related disorders by integrating high throughput genetics, genomics and metabolomics data. This should allow identification of patients with preclinical phenotypes along with those hypertensives that cluster into specific endocrine groups who may benefit from personalised treatment.